MerLion announces FDA approval of finafloxacin otic suspension | American Pharmacists Association
Skip to main contentAdvertisement
Connect Contact UsLogin/Register Join APhA Search form Search Advanced Search LEARNPRACTICEGET INVOLVEDSHOP ABOUTNEWS Search form Search Advanced Search LEARNPRACTICEGET INVOLVEDSHOP ABOUTNEWS Menu LEARNCAREER CENTERJOB SEARCHPATHWAYSRESIDENCIESCONTINUING EDUCATIONHOME STUDY CPELIVE ACTIVITIESTRAINING PROGRAMSAMBULATORY CARE REVIEW AND RECERTIFICATIONTECHNICIANSMY TRAININGPRACTICEMTM CENTRALIMPLEMENTING MTM IN YOUR PRACTICEADVANCING THE VALUE OF MTMMTM RESOURCE LIBRARYIMMUNIZATION CENTERAPhA IMMUNIZATION GUIDELINESADMINISTRATION TECHNIQUEASK THE EXPERTSINFECTIOUS DISEASECOMPOUNDINGFREQUENTLY ASKED QUESTIONSSPECIALTY PHARMACYTOPICS IN PRACTICEPATIENT OUTREACH TOOLSSAFETY NET PROVIDERSAPPOINTMENT BASED MODELGET INVOLVEDPARTICIPATEHOUSE OF DELEGATESAPhA-APPMAPhA-APRSAPhA-ASPNEW PRACTITIONER NETWORKELECTIONSANNUAL MEETING & EXPOSITIONJOINT FEDERAL PHARMACY SEMINARAWARDSJOIN APhAWHY JOIN APhA?RENEW YOUR MEMBERSHIPAPhA CORPORATE SUPPORTERSUSING YOUR APhA BENEFITSADVOCATEISSUESACTIONAPhA-PACPROVIDER STATUSENGAGE COMMUNITIESAMERICAN PHARMACISTS MONTHSHOPSHOP APhA PRODUCTSAPhA E-BOOKSFACULTY RESOURCESLEXICOMP PRODUCTSCORRECTIONS ABOUTWHO WE AREHISTORY OF APhAGOVERNANCE AND LEADERSHIPAPhA DEPARTMENT CONTACTSEXTERNAL SUPPORTEMPLOYMENTTHE PHARMACY PROFESSIONGETTING THE MOST FROM YOUR PHARMACISTNEWSPHARMACY TODAYABOUTDIGITAL READERCURRENT ISSUEPAST ISSUESINFORMATIONAL RESOURCESLETTERS TO THE EDITORADVERTISESUBSCRIBESTUDENT PHARMACISTDIGITAL READERCURRENT ISSUEPAST ISSUESADVERTISEAPhA DRUGINFOLINEJAPhAJPHARMSCICEO BLOGMEDIA RESOURCESAPhA TV NEWS PHARMACY TODAYABOUTDIGITAL READERCURRENT ISSUEPAST ISSUESINFORMATIONAL RESOURCESLETTERS TO THE EDITORADVERTISESUBSCRIBESTUDENT PHARMACISTDIGITAL READERCURRENT ISSUEPAST ISSUESADVERTISEAPhA DRUGINFOLINEJAPhAJPHARMSCICEO BLOGMEDIA RESOURCESAPhA TV Experience Select One That Best Describes you 
Student 
Practitioner 
Scientist Advertisement MerLion announces FDA approval of finafloxacin otic suspension Share This PageFebruary 12, 2015MerLion Pharmaceuticals, a biopharmaceutical company headquartered in Singapore, announced that FDA has approved an otic suspension of finafloxacin (Xtoro) to treat acute otitis externa, also known as "swimmer's ear." The company recently released results from a phase 2 trial showing positive outcomes at all primary and all secondary endpoints.
MerLion Pharmaceuticals, a biopharmaceutical company headquartered in Singapore, announced that FDA has approved an otic suspension of finafloxacin (Xtoro) to treat acute otitis externa, also known as "swimmer's ear." The company recently released results from a phase 2 trial showing positive outcomes at all primary and all secondary endpoints. MerLion's David Dally said finafloxacin is the first novel drug from a Singapore company to gain FDA approval.
MerLion Pharmaceuticals (02/11/2015)
Ad Position: Bottom-Right http://www.merlionpharma.com/?q=node/229 Advertisement
Related Content
block-views-related-content-block
Back to Top LEARNCAREER CENTERCONTINUING EDUCATIONPRACTICEMTM CENTRALIMMUNIZATION CENTERINFECTIOUS DISEASECOMPOUNDINGSPECIALTY PHARMACYTOPICS IN PRACTICEAPPOINTMENT BASED MODELGET INVOLVEDPARTICIPATEJOIN APhAADVOCATEPROVIDER STATUSENGAGE COMMUNITIESAMERICAN PHARMACISTS MONTHSHOPSHOP APhA PRODUCTSAPhA E-BOOKSFACULTY RESOURCESLEXICOMP PRODUCTSCORRECTIONS MEMBER CENTERTHE APhA FOUNDATIONPHARMACY LIBRARYBUYERS GUIDE 
2215 Constitution Avenue NW, Washington, DC 20037? 2015 American Pharmacists Association All Rights Reserved.tel. 202.628.4410fax 202.783.2351SitemapPrivacy Policy Terms of Use View in Desktop ModeLogin/Register PHARMACY TODAYABOUTDIGITAL READERCURRENT ISSUEPAST ISSUESINFORMATIONAL RESOURCESLETTERS TO THE EDITORADVERTISESUBSCRIBESTUDENT PHARMACISTDIGITAL READERCURRENT ISSUEPAST ISSUESADVERTISEAPhA DRUGINFOLINEJAPhAJPHARMSCICEO BLOGMEDIA RESOURCESAPhA TV Featured 
Policy 101: Medically underserved communities 
Olaparib: new drug for advanced ovarian cancerCAREER CENTERJOB SEARCHPATHWAYSRESIDENCIESCONTINUING EDUCATIONHOME STUDY CPELIVE ACTIVITIESTRAINING PROGRAMSAMBULATORY CARE REVIEW AND RECERTIFICATIONTECHNICIANSMY TRAINING Featured
Our profession's storytellers get the word out!
Pharmacist license revocation reversedMTM CENTRALIMPLEMENTING MTM IN YOUR PRACTICEADVANCING THE VALUE OF MTMMTM RESOURCE LIBRARYIMMUNIZATION CENTERAPhA IMMUNIZATION GUIDELINESADMINISTRATION TECHNIQUEASK THE EXPERTSINFECTIOUS DISEASECOMPOUNDINGFREQUENTLY ASKED QUESTIONSSPECIALTY PHARMACYTOPICS IN PRACTICEPATIENT OUTREACH TOOLSSAFETY NET PROVIDERSAPPOINTMENT BASED MODEL Featured
New Mexican pharmacists create care transitions program
Choe enhances health care for Michigan patients PARTICIPATEHOUSE OF DELEGATESAPhA-APPMAPhA-APRSAPhA-ASPNEW PRACTITIONER NETWORKELECTIONSANNUAL MEETING & EXPOSITIONJOINT FEDERAL PHARMACY SEMINARAWARDSJOIN APhAWHY JOIN APhA?RENEW YOUR MEMBERSHIPAPhA CORPORATE SUPPORTERSUSING YOUR APhA BENEFITSADVOCATEISSUESACTIONAPhA-PACPROVIDER STATUSENGAGE COMMUNITIESAMERICAN PHARMACISTS MONTH Featured 
Give clear, explicit directions to patients
Pharmacist Aldrich reduces readmissions, incorrect med usage in NMSHOP APhA PRODUCTSAPhA E-BOOKSFACULTY RESOURCESLEXICOMP PRODUCTSCORRECTIONS Featured
Pharmacy Technician Skills-Building Manual WHO WE AREHISTORY OF APhAGOVERNANCE AND LEADERSHIPAPhA DEPARTMENT CONTACTSEXTERNAL SUPPORTEMPLOYMENTTHE PHARMACY PROFESSIONGETTING THE MOST FROM YOUR PHARMACIST Featured
APhA2015: Let's advance as one!
Today's Perspective: Remembering the basics
View the original article here
0 comments
Post a Comment